Company news

Eli Lilly and Company news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio

October 29, 2026

Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial

October 28, 2026

Patrik Jonsson to retire after 36 years; Ilya Yuffa named president, Lilly Global Markets

October 27, 2026

Lilly declares fourth-quarter 2026 dividend

October 26, 2026

New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer

October 25, 2026

Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026

October 24, 2026

Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. sites since 2020

October 22, 2026

Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis

October 19, 2026

Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress

October 18, 2026

Lilly confirms date and conference call for third-quarter 2026 financial results announcement

October 15, 2026

New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year

October 15, 2026

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity

October 9, 2026

Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions

October 5, 2026

Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL

October 2, 2026

Lilly Pulitzer supports The Pink Agenda with 'petals with a purpose' Print capsule for breast cancer awareness month

October 1, 2026

Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease

October 1, 2026

EADV 2026: Long-Term Disease Control for up to Five Years in Patients With Moderate-to-Severe Atopic Dermatitis Treated With Lebrikizumab

October 1, 2026

Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study

September 30, 2026

Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes

September 30, 2026

New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis

September 30, 2026

Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison

September 29, 2026

Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICs

September 28, 2026

FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata

September 25, 2026

U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes

September 24, 2026

Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020

September 21, 2026

U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer

September 18, 2026

Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health

September 15, 2026

Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions

September 11, 2026

Obesity Market Set for Explosive 27% CAGR Growth by 2036, Fueled by 7 Promising Emerging Therapies | DelveInsight

September 10, 2026

Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference

September 1, 2026

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity

August 31, 2026

Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases

August 31, 2026

FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes

August 28, 2026

Eli Lilly and Company - Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study

August 27, 2026

Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study

August 26, 2026

Amplitude Therapeutics and Lilly Enter Strategic Collaboration to Develop Trans-Amplifying RNA Vaccines for Infectious Diseases

August 19, 2026

Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market

August 12, 2026

Veeva Vault CRM Selected by Eli Lilly and Company

August 11, 2026

Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress

August 5, 2026

Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer

August 3, 2026

Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C

July 23, 2026

Lilly confirms date and conference call for second-quarter 2026 financial results announcement

July 22, 2026

Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200

July 17, 2026

The Biotech Growth Trust PLC - Eli Lilly to acquire BIOG portfolio company, AtaiBeckley Inc.

July 17, 2026

Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions

July 16, 2026

Correction: Eli Lilly and Company

July 9, 2026

Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment

July 9, 2026

Health Canada approves Mounjaro® (tirzepatide) for use in children 10 years and older living with type 2 diabetes

July 7, 2026

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios in Mainland China

July 1, 2026

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

June 29, 2026

Older news releases →

Calls

The 5 newest of 32 calls. Every call is listed under its year.

Decks

The 5 newest of 32 decks. Every deck is listed under its year.